carvedilol has been researched along with labetalol in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (22.45) | 18.7374 |
| 1990's | 17 (34.69) | 18.2507 |
| 2000's | 9 (18.37) | 29.6817 |
| 2010's | 9 (18.37) | 24.3611 |
| 2020's | 3 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Baker, JG | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| He, X; Hu, B; Li, C; Ma, Y; Wang, J; Wang, Y; Xue, W; Zhang, F; Zhang, T | 1 |
| Chang, Q; Chen, Z; Hu, G; Hu, L; Li, Q; Long, J | 1 |
| Graham, BR; Prichard, BN; Tomlinson, B; Walden, RJ | 1 |
| Rahn, KH | 2 |
| Lund-Johansen, P | 1 |
| Lund-Johansen, P; Omvik, P | 2 |
| Ruffolo, RR; Sauermelch, CF; Willette, RN | 2 |
| Bussiere, JL; Durier, P; Gayet, JL; Ollivier, JP | 1 |
| Sponer, G; Strein, K | 1 |
| Prichard, BN | 1 |
| DeWolf, R; Gellai, M; Ruffolo, RR | 1 |
| Bartsch, W; Müller-Beckmann, B; Sponer, G; Strein, K | 1 |
| Bartsch, W; Böhm, E; Hooper, RG; Sponer, G; Strein, K | 1 |
| Cronin, CJ; Graham, BR; Prichard, BN; Tomlinson, B | 1 |
| Colindres, RE; Cubeddu, LX; Fuenmayor, N; Powell, JR; Varin, F; Villagra, VG | 2 |
| Conway, EL; Drummer, OH; Louis, WJ; McNeil, JJ; Workman, BS | 1 |
| Mikami, H; Ogihara, T | 1 |
| Lefflerová, K; Widimský, J | 1 |
| Akashi, A; Hashimoto, H; Kanda, A; Tanaka, M | 1 |
| Bompart, F; Graham, BR; Liu, JB; Prichard, BN; Tomlinson, B | 1 |
| van Zwieten, PA | 1 |
| Guy, S; McDermott, BJ; Riddell, JG; Shanks, RG; Tham, TC | 1 |
| Frishman, W; Moser, M | 1 |
| Heintz, B; Kirsten, D; Kirsten, R; Nelson, K | 1 |
| Abuin, L; Cotecchia, S; Lattion, A; Nenniger-Tosato, M | 1 |
| Donckier, J; Godfraind, T; Heyndrickx, GR; Kyselovic, J; Massart, PE; Wibo, M | 1 |
| Imaizumi, T; Mizuta, Y | 1 |
| Cockcroft, JR; Pedersen, ME | 1 |
| Bakris, G | 1 |
| Ferdinand, KC; Giles, TD; Manrique, C; Sowers, JR | 1 |
| Baumann, MH; Kiyatkin, EA; Ren, S; Shaham, Y; Wakabayashi, KT | 1 |
| Laugerotte, A; Wong, GW; Wright, JM | 1 |
| Madias, JE | 1 |
| Tornvall, P; Y-Hassan, S | 1 |
| Berard-Collins, CM; Boscardin, WJ; Bosco, E; Daiello, LA; Dore, DD; Hersey, M; Lee, Y; Mor, V; Shah, NR; Sharmin, S; Steinman, MA; Zullo, AR | 1 |
| Andresen, BT; Chang, A; Chen, S; Cleveland, KH; Guo, L; Huang, KM; Huang, Y; Liang, S | 1 |
| Jacobsen, SJ; Kalantar-Zadeh, K; Kovesdy, CP; Lee, MS; Neyer, JR; Shaw, SF; Shi, J; Sim, JJ; Zhou, H | 1 |
15 review(s) available for carvedilol and labetalol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical experience with dual-acting drugs in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Celiprolol; Humans; Hypertension; Labetalol; Propanolamines; Vasodilator Agents | 1992 |
The influence of vasodilating beta-blockers on cardiac function and vascular resistance in essential hypertension.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output; Carvedilol; Hemodynamics; Humans; Hypertension; Labetalol; Male; Propanolamines; Pyridazines; Vascular Resistance; Vasodilator Agents | 1992 |
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Celiprolol; Coronary Disease; Heart Failure; Hemodynamics; Humans; Labetalol; Propanolamines; Vasodilator Agents; Ventricular Function, Left | 1990 |
Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Disease; Hemodynamics; Humans; Labetalol; Myocardial Infarction; Propanolamines | 1990 |
Antihypertensive compounds with combined actions.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Celiprolol; Humans; Hypertension; Labetalol; Propanolamines | 1987 |
Betablockers in the treatment of hypertension (with special emphasis on betablockers with ISA). A review.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Celiprolol; Humans; Hypertension; Labetalol; Middle Aged; Pindolol; Propanolamines | 1988 |
An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiovascular Diseases; Carvedilol; Hemodynamics; Humans; Labetalol; Propanolamines | 1993 |
Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aging; Antioxidants; Blood Pressure; Carbazoles; Carvedilol; Humans; Hypertension; Labetalol; Propanolamines; Vasodilator Agents | 1998 |
Clinical pharmacokinetics of vasodilators. Part II.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Alprostadil; Amrinone; Carbazoles; Carvedilol; Enoximone; Female; Humans; Iloprost; Imidazoles; Indoramin; Isosorbide Dinitrate; Labetalol; Milrinone; Molsidomine; Nitroglycerin; Nitroprusside; Oxyfedrine; Pentaerythritol Tetranitrate; Phosphodiesterase Inhibitors; Piperazines; Prazosin; Pregnancy; Propanolamines; Pyridones; Theophylline; Trapidil; Vasodilator Agents | 1998 |
[Alpha beta-blockers for patients with hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Complications; Evidence-Based Medicine; Heart Failure; Humans; Hyperlipidemias; Hypertension; Labetalol; Prognosis; Propanolamines | 2006 |
The vasodilatory beta-blockers.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Antioxidants; Atenolol; Benzopyrans; Blood Pressure; Carbazoles; Cardiac Output; Cardiovascular Diseases; Carvedilol; Endothelium, Vascular; Ethanolamines; Hemodynamics; Humans; Labetalol; Nebivolol; Propanolamines; Vascular Resistance; Vasodilation; Ventricular Function, Left | 2007 |
An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Blood Pressure; Carbazoles; Cardiac Output; Carvedilol; Ethanolamines; Humans; Hypertension; Labetalol; Nebivolol; Propanolamines; Vascular Resistance; Vasodilation | 2009 |
Realities of newer beta-blockers for the management of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolamines; Heart Failure; Humans; Hypertension; Labetalol; Nebivolol; Propanolamines; Treatment Outcome | 2009 |
Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Essential Hypertension; Heart Rate; Humans; Hypertension; Labetalol; Propanolamines; Randomized Controlled Trials as Topic; Withholding Treatment | 2015 |
8 trial(s) available for carvedilol and labetalol
| Article | Year |
|---|---|
Clinical pharmacology of carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double-Blind Method; Hemodynamics; Humans; Labetalol; Male; Norepinephrine; Phenylephrine; Propanolamines; Vasodilator Agents | 1992 |
Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Drug Administration Schedule; Female; Heart Rate; Humans; Hypertension; Labetalol; Male; Middle Aged; Multicenter Studies as Topic; Propanolamines; Randomized Controlled Trials as Topic | 1990 |
Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double-Blind Method; Heart Rate; Hemodynamics; Humans; Labetalol; Male; Physical Exertion; Pindolol; Propanolamines; Propranolol; Random Allocation | 1987 |
Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Blood Pressure; Carbazoles; Carvedilol; Half-Life; Heart Rate; Humans; Isoproterenol; Labetalol; Phenylephrine; Propanolamines; Random Allocation; Vasodilation | 1987 |
A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Age Factors; Aged; Biological Availability; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Food; Half-Life; Heart Rate; Humans; Infusions, Intravenous; Labetalol; Male; Middle Aged; Propanolamines; Random Allocation | 1987 |
Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Cold Temperature; Double-Blind Method; Exercise; Heart Rate; Hemodynamics; Humans; Hydralazine; Isoproterenol; Labetalol; Male; Middle Aged; Phenylephrine; Posture; Propanolamines; Propranolol; Vasodilator Agents | 1988 |
Clinical pharmacology of carvedilol in normal volunteers.
Topics: Adult; Angiotensin II; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Rate; Humans; Isoproterenol; Kinetics; Labetalol; Male; Phenylephrine; Propanolamines; Random Allocation; Receptors, Adrenergic | 1987 |
The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Exercise; Heart Rate; Humans; Isoproterenol; Labetalol; Male; Phenylephrine; Propanolamines; Vasodilator Agents | 1995 |
26 other study(ies) available for carvedilol and labetalol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3 | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
Topics: A549 Cells; Carvedilol; Cell Proliferation; Cell Survival; Cytochrome P-450 CYP1B1; Density Functional Theory; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Repositioning; Drug Screening Assays, Antitumor; Humans; Melanoma; Molecular Docking Simulation; Molecular Structure; Propanols; Skin Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzeneacetamides; Calcium Channel Blockers; Carbazoles; Carvedilol; Doxazosin; Female; Guanidines; Hemodynamics; Humans; Indoles; Labetalol; Male; Middle Aged; Nisoldipine; Pinacidil; Potassium Channels; Prazosin; Propanolamines; Propylamines; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Tiapamil Hydrochloride | 1990 |
Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation.
Topics: Adrenergic beta-Antagonists; Anesthesia; Animals; Blood Pressure; Carbazoles; Carvedilol; Heart Rate; Hemodynamics; Labetalol; Male; Microcirculation; Propanolamines; Rats; Rats, Inbred Strains; Regional Blood Flow; Skin; Ultrasonics; Vasodilation | 1990 |
Effect of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Glomerular Filtration Rate; Kidney; Labetalol; Male; p-Aminohippuric Acid; Propanolamines; Rats; Rats, Inbred SHR; Renal Circulation; Vascular Resistance; Water-Electrolyte Balance | 1990 |
Local cutaneous hemodynamic effects of carvedilol and labetalol in the anesthetized rat.
Topics: Anesthesia; Animals; Blood Pressure; Carbazoles; Carvedilol; Heart Rate; Labetalol; Male; Microcirculation; Propanolamines; Rats; Rats, Inbred Strains; Regional Blood Flow; Skin; Vascular Resistance; Vasodilator Agents | 1990 |
Studies on the mode of vasodilating action of carvedilol.
Topics: Animals; Aorta; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; In Vitro Techniques; Labetalol; Muscle Relaxation; Nitroprusside; Norepinephrine; Propanolamines; Rats; Rats, Inbred Strains; Vasodilation; Vasodilator Agents | 1987 |
Evaluation of the risk for drug-induced postural hypotension in an experimental model: investigations with carvedilol, prazosin, labetalol, and guanethidine.
Topics: Animals; Blood Pressure; Carbazoles; Carvedilol; Disease Models, Animal; Guanethidine; Hypotension, Orthostatic; Labetalol; Prazosin; Propanolamines; Rabbits; Risk; Vasodilator Agents | 1987 |
[Clinical application of adrenoceptor blockers in the treatment of hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Hypertension; Labetalol; Prazosin; Propanolamines; Quinazolines | 1989 |
Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Decerebrate State; Dose-Response Relationship, Drug; Drug Interactions; Hydralazine; Hypertension; Labetalol; Prazosin; Propanolamines; Rats; Rats, Inbred SHR; Vasodilator Agents | 1988 |
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Benzeneacetamides; Carbazoles; Carvedilol; Diet, Sodium-Restricted; Diltiazem; Dipeptides; Doxazosin; Exercise; Felodipine; Female; Hemodynamics; Humans; Hypertension; Ketanserin; Labetalol; Lisinopril; Longitudinal Studies; Male; Middle Aged; Propanolamines | 1993 |
Constitutively active mutants of the beta1-adrenergic receptor.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Amino Acid Substitution; Betaxolol; Carbazoles; Carvedilol; Cell Line; Cyclic AMP; Epinephrine; Humans; Imidazoles; Isoproterenol; Labetalol; Point Mutation; Practolol; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Recombinant Proteins; Timolol | 1999 |
Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene overexpression after aortic banding.
Topics: Actins; Animals; Antihypertensive Agents; Aortic Diseases; Blood Pressure; Carbazoles; Carotid Arteries; Carvedilol; Constriction, Pathologic; Dihydropyridines; Disease Models, Animal; Endothelin-1; Endothelins; Gene Expression; Heart Rate; Heart Ventricles; Hypertrophy, Left Ventricular; Labetalol; Ligation; Male; Myocardium; Organ Size; Propanolamines; Protein Precursors; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger | 1999 |
Clinically Relevant Pharmacological Strategies That Reverse MDMA-Induced Brain Hyperthermia Potentiated by Social Interaction.
Topics: Animals; Antipsychotic Agents; Body Temperature; Brain; Carbazoles; Carvedilol; Clozapine; Fever; Hallucinogens; Homeostasis; Labetalol; Male; N-Methyl-3,4-methylenedioxyamphetamine; Propanolamines; Rats, Long-Evans; Skin; Social Behavior; Sympathomimetics; Vasodilator Agents | 2016 |
Metoprolol, propranolol, carvedilol, or labetalol for patients with Takotsubo syndrome?
Topics: Carvedilol; Humans; Labetalol; Metoprolol; Propranolol; Takotsubo Cardiomyopathy | 2018 |
Reply to: metoprolol, or propranolol, or carvedilol, or labetalol, for patients with takotsubo syndrome?
Topics: Carvedilol; Humans; Labetalol; Metoprolol; Propranolol; Takotsubo Cardiomyopathy | 2018 |
Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Blood Glucose; Carvedilol; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hyperglycemia; Hypoglycemia; Labetalol; Logistic Models; Male; Medicare; Myocardial Infarction; Nebivolol; Nursing Homes; Odds Ratio; Retrospective Studies; Treatment Outcome; United States | 2018 |
Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors.
Topics: Adrenergic beta-Antagonists; Alprenolol; Animals; Carvedilol; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Epidermal Growth Factor; Inhibitory Concentration 50; Labetalol; Ligands; Mice; Mice, Inbred C57BL; Receptors, Adrenergic; Receptors, Adrenergic, beta; RNA, Small Interfering; Signal Transduction; Skin; Skin Neoplasms; Ultraviolet Rays | 2019 |
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Death; Cohort Studies; Female; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Labetalol; Logistic Models; Male; Metoprolol; Middle Aged; Mortality; Nadolol; Proportional Hazards Models; Propranolol; Protective Factors; Renal Dialysis; Retrospective Studies; Risk; Risk Factors | 2021 |